[{"title":"Vaccin contre la COVID-19 de Pfizer-BioNTech - Demande pour l\u2019usage p\u00e9diatrique","brand_name":"Vaccin contre la COVID-19 de Pfizer-BioNTech - Demande pour l\u2019usage p\u00e9diatrique (12 \u00e0 15 ans)","company_name":"BioNTech Manufacturing GmbH","ingredient":"tozinameran","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"36","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Pfizer-BioNTech COVID-19 Vaccine  - Application for Pediatric Use","brand_name":"Pfizer-BioNTech COVID-19 Vaccine - Application for Pediatric Use (ages 12-15)","company_name":"BioNTech Manufacturing GmbH","ingredient":"tozinameran","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"36","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Demo Vaccine","brand_name":"Demo Vaccine","company_name":"Test Company","ingredient":"Demo Vaccine Ing","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"33","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Demo Vaccine","brand_name":"Demo Vaccine","company_name":"Test Company","ingredient":"Demo Vaccine Ing","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"33","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Casirivimab (casirivimab) et imdevimab (imdevimab)","brand_name":"Casirivimab et imdevimab","company_name":"Hoffmann-La Roche Limited","ingredient":"casirivimab \/ imdevimab","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"29","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022fr\u0022\u003ETraitement\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Casirivimab (casirivimab) and imdevimab (imdevimab)","brand_name":"Casirivimab and imdevimab","company_name":"Hoffmann-La Roche Limited","ingredient":"casirivimab \/ imdevimab","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"29","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022en\u0022\u003ETreatment\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Covishield (ChAdOx1 [recombinant])","brand_name":"Covishield","company_name":"Verity Pharmaceuticals Inc\/Serum Institute of India","ingredient":"ChAdOx1 [recombinant]","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"28","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Covishield (ChAdOx1 [recombinant])","brand_name":"Covishield","company_name":"Verity Pharmaceuticals Inc\/Serum Institute of India","ingredient":"ChAdOx1 [recombinant]","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"28","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Vaccin d\u0026#039;AstraZeneca contre la COVID-19 (ChAdOx1-S)","brand_name":"Vaccin d\u0026#039;AstraZeneca contre la COVID-19 (ChAdOx1-S)","company_name":"AstraZeneca Canada Inc","ingredient":"ChAdOx1-S","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"\u003Ctime datetime=\u00222021-02-23T12:00:00Z\u0022\u003ETue, 02\/23\/2021 - 12:00\u003C\/time\u003E\n","language":"Fran\u00e7ais","body_text":null,"resources":[{"id":"73","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-19T12:00:00Z\u0022\u003EFri, 02\/19\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EDrugs included on this list are called \u0022designated drugs\u0022 and are eligible for the exceptional importation and sale provisions provided for in the Interim Order. The list, which will be updated as required, is incorporated by reference in the IO and is maintained by Health Canada.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/covid19-interim-order-drugs-medical-devices-special-foods\/information-provisions-related-drugs-biocides\/list.html\u0022\u003EDrug Shortages\u003C\/a\u003E","various_dates":"No"},{"id":"74","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada.\u00a0La communication la plus r\u00e9cente se trouve ici. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada et peuvent \u00eatre consult\u00e9es en cliquant sur la section \u0022 Avis \u0022.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/span\u003E","various_dates":"No"},{"id":"75","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/\u0022\u003EEffets secondaires suivant l\u2019immunisation\u003C\/a\u003E","various_dates":"No"},{"id":"76","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EConditions de l\u2019autorisation\u003C\/span\u003E","various_dates":"No"},{"id":"77","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22AstraZeneca%20COVID-19%20Vaccine%22%20OU%20%22ChAdOx1-S%22\u0022\u003EAvis\u003C\/a\u003E","various_dates":"Yes"},{"id":"78","bundle":"vaccine_resources","audience":["Health Care Professionals"],"description":"\u003Cp\u003EInformations destin\u00e9es aux professionnels de la sant\u00e9 sur l\u0027utilisation de seringues et d\u0027aiguilles \u00e0 faible volume mort.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EGuide d\u0026#039;administration pour les seringues et les aiguilles \u00e0 faible volume mort\u003C\/span\u003E","various_dates":"No"}],"nid":"26","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/covid19-interim-order-drugs-medical-devices-special-foods\/information-provisions-related-drugs-biocides\/list.html\u0022\u003EDrug Shortages\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EDrugs included on this list are called \u0022designated drugs\u0022 and are eligible for the exceptional importation and sale provisions provided for in the Interim Order. The list, which will be updated as required, is incorporated by reference in the IO and is maintained by Health Canada.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-19T12:00:00Z\u0022\u003EFri, 02\/19\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada.\u00a0La communication la plus r\u00e9cente se trouve ici. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada et peuvent \u00eatre consult\u00e9es en cliquant sur la section \u0022 Avis \u0022.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/\u0022\u003EEffets secondaires suivant l\u2019immunisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EConditions de l\u2019autorisation\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22AstraZeneca%20COVID-19%20Vaccine%22%20OU%20%22ChAdOx1-S%22\u0022\u003EAvis\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EGuide d\u0026#039;administration pour les seringues et les aiguilles \u00e0 faible volume mort\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformations destin\u00e9es aux professionnels de la sant\u00e9 sur l\u0027utilisation de seringues et d\u0027aiguilles \u00e0 faible volume mort.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"AstraZeneca COVID-19 Vaccine (ChAdOx1-S)","brand_name":"AstraZeneca COVID-19 Vaccine","company_name":"AstraZeneca Canada Inc","ingredient":"ChAdOx1-S","status":"Authorized By Interim Order","date_of_approval":"\u003Ctime datetime=\u00222021-02-23T12:00:00Z\u0022\u003ETue, 02\/23\/2021 - 12:00\u003C\/time\u003E\n","language":"English","body_text":null,"resources":[{"id":"73","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-19T12:00:00Z\u0022\u003EFri, 02\/19\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EDrugs included on this list are called \u0022designated drugs\u0022 and are eligible for the exceptional importation and sale provisions provided for in the Interim Order. The list, which will be updated as required, is incorporated by reference in the IO and is maintained by Health Canada.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/covid19-interim-order-drugs-medical-devices-special-foods\/information-provisions-related-drugs-biocides\/list.html\u0022\u003EDrug Shortages\u003C\/a\u003E","various_dates":"No"},{"id":"74","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-03-01T00:11:11Z\u0022\u003EMon, 03\/01\/2021 - 00:11\u003C\/time\u003E\n","description":"\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. The most recent communication can be found here. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database and can be found by clicking on the \u0022Advisories\u0022 section.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EHealth Product Risk Communications\u003C\/span\u003E","various_dates":"No"},{"id":"75","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/\u0022\u003EAdverse Events Following Immunization\u003C\/a\u003E","various_dates":"No"},{"id":"76","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EAuthorization Terms \u0026amp; Conditions\u003C\/span\u003E","various_dates":"No"},{"id":"77","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22AstraZeneca%20COVID-19%20Vaccine%22%20OR%20%22ChAdOx1-S%22\u0022\u003EAdvisories\u003C\/a\u003E","various_dates":"Yes"},{"id":"78","bundle":"vaccine_resources","audience":["Health Care Professionals"],"description":"\u003Cp\u003EThe steps to AstraZeneca COVID-19 Vaccination. Your guide to proper storage, handling, and administration of the vaccine.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EStorage, handling, and administration\u003C\/span\u003E","various_dates":"No"}],"nid":"26","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/covid19-interim-order-drugs-medical-devices-special-foods\/information-provisions-related-drugs-biocides\/list.html\u0022\u003EDrug Shortages\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EDrugs included on this list are called \u0022designated drugs\u0022 and are eligible for the exceptional importation and sale provisions provided for in the Interim Order. The list, which will be updated as required, is incorporated by reference in the IO and is maintained by Health Canada.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-19T12:00:00Z\u0022\u003EFri, 02\/19\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-03T12:12:12Z\u0022\u003EWed, 03\/03\/2021 - 12:12\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EHealth Product Risk Communications\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. The most recent communication can be found here. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database and can be found by clicking on the \u0022Advisories\u0022 section.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-01T00:11:11Z\u0022\u003EMon, 03\/01\/2021 - 00:11\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/\u0022\u003EAdverse Events Following Immunization\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EAuthorization Terms \u0026amp; Conditions\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22AstraZeneca%20COVID-19%20Vaccine%22%20OR%20%22ChAdOx1-S%22\u0022\u003EAdvisories\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EStorage, handling, and administration\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe steps to AstraZeneca COVID-19 Vaccination. Your guide to proper storage, handling, and administration of the vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"New Product 1 -french mod2","brand_name":"New product -french mod2","company_name":"Test Company","ingredient":"new ingredient2","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"25","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"New Product 1- update","brand_name":"New product-update","company_name":"Test Company","ingredient":"new ingredient","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"25","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Colchicine","brand_name":"Colchicine","company_name":"Pendopharm Division of Pharmascience Inc","ingredient":"colchicine","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"18","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022fr\u0022\u003ETraitement\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Colchicine","brand_name":"Colchicine","company_name":"Pendopharm Division of Pharmascience Inc","ingredient":"colchicine","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"18","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022en\u0022\u003ETreatment\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Favipiravir (favipiravir)","brand_name":"Favipiravir","company_name":"Dr Reddys Laboratories Ltd","ingredient":"favipiravir","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"17","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022fr\u0022\u003ETraitement\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Favipiravir (favipiravir)","brand_name":"Favipiravir","company_name":"Dr Reddys Laboratories Ltd","ingredient":"favipiravir","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"17","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022en\u0022\u003ETreatment\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Vaccin contre la COVID-19 de Pfizer-Biontech (tozinam\u00e9ran)","brand_name":"Vaccin contre la COVID-19 de Pfizer-Biontech","company_name":"BioNTech Manufacturing GmbH","ingredient":"tozinam\u00e9ran","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","language":"Fran\u00e7ais","body_text":"\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Ch2\u003ERenseignements suppl\u00e9mentaires\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/pfizer-biontech.html\u0022\u003ECe que vous devriez savoir\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/pfizer-biontech\/autorisation.html\u0022\u003EInformations relatives \u00e0 l\u0027autorisation\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/pfizer-biontech\/surveillance.html\u0022\u003ESurveillance continue\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n","resources":[{"id":"27","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/vaccin-contre-la-covid-19-de-pfizer-biontech.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E","various_dates":"No"},{"id":"28","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-pm1.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E","various_dates":"No"},{"id":"40","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222021-02-12T12:00:00Z\u0022\u003EFri, 02\/12\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin contre la COVID-19 de Pfizer-BioNTech.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etiquette.pdf\u0022\u003E\u00c9tiquette du produit\u003C\/a\u003E","various_dates":"No"},{"id":"29","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00730\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E","various_dates":"No"},{"id":"30","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00510\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E","various_dates":"No"},{"id":"70","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00510\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E","various_dates":"No"},{"id":"37","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-lettre.pdf\u0022\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/a\u003E","various_dates":"No"},{"id":"67","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/\u0022\u003EEffets secondaires suivant l\u2019immunisation\u003C\/a\u003E","various_dates":"Yes"},{"id":"35","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EPlan de gestion des risques\u003C\/span\u003E","various_dates":"No"},{"id":"31","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003ERenseignements cliniques\u003C\/span\u003E","various_dates":"No"},{"id":"32","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E","various_dates":"No"},{"id":"33","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OU%20%22tozinameran%22\u0022\u003EAvis\u003C\/a\u003E","various_dates":"No"},{"id":"38","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin contre la COVID-19 de Pfizer-BioNTech. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin contre la COVID-19 de Pfizer-BioNTech.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etapes-administration.pdf\u0022\u003EConservation, manipulation et administration\u003C\/a\u003E","various_dates":"No"},{"id":"39","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EDirectives d\u2019exp\u00e9dition et de manipulation. Pour vous assurer que les contr\u00f4les appropri\u00e9s sont mis en place, veuillez consulter la fiche des donn\u00e9es de s\u00e9curit\u00e9 de la glace s\u00e8che avant d\u2019acc\u00e9der au contenu du conteneur d\u2019exp\u00e9dition isotherme, et consultez votre service de sant\u00e9 et s\u00e9curit\u00e9 au travail.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-directives-expedition-manipulation.pdf\u0022\u003EDirectives d\u2019exp\u00e9dition et de manipulation\u003C\/a\u003E","various_dates":"No"}],"nid":"16","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/vaccin-contre-la-covid-19-de-pfizer-biontech.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-02T14:02:02Z\u0022\u003ETue, 02\/02\/2021 - 14:02\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-pm1.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etiquette.pdf\u0022\u003E\u00c9tiquette du produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin contre la COVID-19 de Pfizer-BioNTech.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-12T12:00:00Z\u0022\u003EFri, 02\/12\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00730\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00510\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00510\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-08T00:12:12Z\u0022\u003EMon, 02\/08\/2021 - 00:12\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-lettre.pdf\u0022\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/\u0022\u003EEffets secondaires suivant l\u2019immunisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EPlan de gestion des risques\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003ERenseignements cliniques\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OU%20%22tozinameran%22\u0022\u003EAvis\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etapes-administration.pdf\u0022\u003EConservation, manipulation et administration\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin contre la COVID-19 de Pfizer-BioNTech. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin contre la COVID-19 de Pfizer-BioNTech.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-directives-expedition-manipulation.pdf\u0022\u003EDirectives d\u2019exp\u00e9dition et de manipulation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EDirectives d\u2019exp\u00e9dition et de manipulation. Pour vous assurer que les contr\u00f4les appropri\u00e9s sont mis en place, veuillez consulter la fiche des donn\u00e9es de s\u00e9curit\u00e9 de la glace s\u00e8che avant d\u2019acc\u00e9der au contenu du conteneur d\u2019exp\u00e9dition isotherme, et consultez votre service de sant\u00e9 et s\u00e9curit\u00e9 au travail.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"Vaccin de Moderna contre la COVID-19 (ARNm-1273 SRAS-CoV-2)","brand_name":"Vaccin de Moderna contre la COVID-19","company_name":"Moderna Therapeutics Inc","ingredient":"ARNm-1273 SRAS-CoV-2","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","language":"Fran\u00e7ais","body_text":"\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Ch2\u003ERenseignements suppl\u00e9mentaires\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/moderna.html\u0022\u003ECe que vous devriez savoir\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/moderna\/autorisation.html\u0022\u003EInformations relatives \u00e0 l\u0027autorisation\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/vaccins\/moderna\/surveillance.html\u0022\u003ESurveillance continue\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n","resources":[{"id":"53","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/vaccin-de-moderna-contre-la-covid-19.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E","various_dates":"No"},{"id":"54","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-pm1.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E","various_dates":"No"},{"id":"55","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin de Moderna contre la COVID-19.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-etiquette.pdf\u0022\u003E\u00c9tiquette du produit\u003C\/a\u003E","various_dates":"No"},{"id":"56","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00736\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E","various_dates":"No"},{"id":"57","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-06T12:00:00Z\u0022\u003EWed, 01\/06\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00511\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E","various_dates":"No"},{"id":"69","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-06T13:00:00Z\u0022\u003EWed, 01\/06\/2021 - 13:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00511\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E","various_dates":"No"},{"id":"58","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-lettre-20201223.pdf\u0022\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/a\u003E","various_dates":"No"},{"id":"66","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EEffets secondaires suivant l\u2019immunisation\u003C\/span\u003E","various_dates":"No"},{"id":"59","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EPlan de gestion des risques\u003C\/span\u003E","various_dates":"No"},{"id":"60","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003ERenseignements cliniques\u003C\/span\u003E","various_dates":"No"},{"id":"61","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E","various_dates":"No"},{"id":"62","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Vaccin%20de%20Moderna%20contre%20la%20COVID-19%22%20OU%20%22ARNm-1273%20SRAS-CoV-2%22\u0022\u003EAvis\u003C\/a\u003E","various_dates":"Yes"},{"id":"63","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin de Moderna contre la COVID-19. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin de Moderna contre la COVID-19.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-entreposage-manipulation.pdf\u0022\u003EConservation, manipulation et administration\u003C\/a\u003E","various_dates":"No"}],"nid":"15","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/vaccin-de-moderna-contre-la-covid-19.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-pm1.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-etiquette.pdf\u0022\u003E\u00c9tiquette du produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin de Moderna contre la COVID-19.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00736\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00511\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-06T12:00:00Z\u0022\u003EWed, 01\/06\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00511\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-06T13:00:00Z\u0022\u003EWed, 01\/06\/2021 - 13:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-lettre-20201223.pdf\u0022\u003ECommunications des risques li\u00e9s aux produits de sant\u00e9\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes communications des risques li\u00e9s aux produits de sant\u00e9 sont publi\u00e9es pour informer les professionnels de la sant\u00e9 des probl\u00e8mes pouvant inclure l\u2019innocuit\u00e9 ou l\u0027efficacit\u00e9 d\u0027un produit. Il s\u0027agit d\u0027une lettre \u00e9mise par le d\u00e9tenteur d\u0027une autorisation de mise sur le march\u00e9 dont le contenu est approuv\u00e9 par Sant\u00e9 Canada. Toutes les CRPSs sont affich\u00e9es dans la base de donn\u00e9es des rappels et des alertes de s\u00e9curit\u00e9 de Sant\u00e9 Canada.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EEffets secondaires suivant l\u2019immunisation\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EPlan de gestion des risques\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003ERenseignements cliniques\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\n\u003Cp\u003ESera publi\u00e9e avant le 31 mars 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Vaccin%20de%20Moderna%20contre%20la%20COVID-19%22%20OU%20%22ARNm-1273%20SRAS-CoV-2%22\u0022\u003EAvis\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-entreposage-manipulation.pdf\u0022\u003EConservation, manipulation et administration\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin de Moderna contre la COVID-19. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin de Moderna contre la COVID-19.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"JNJ-78436735\/Ad26.COV2.S","brand_name":"JNJ-78436735\/Ad26.COV2.S","company_name":"Janssen Inc","ingredient":"Ad26.COV2.S","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"14","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Vaccin d\u2019AstraZeneca contre la COVID-19 (ChAdOx1-S)","brand_name":"Vaccin d\u2019AstraZeneca contre la COVID-19","company_name":"AstraZeneca Canada Inc","ingredient":"ChAdOx1-S","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[],"nid":"13","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022fr\u0022\u003EVaccin\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Bamlanivimab (bamlanivimab)","brand_name":"Bamlanivimab","company_name":"Eli Lilly Canada Inc","ingredient":"bamlanivimab","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":null,"language":"Fran\u00e7ais","body_text":null,"resources":[{"id":"17","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/bamlanivimab-fr.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E","various_dates":"No"},{"id":"18","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-pm1-fr.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E","various_dates":"No"},{"id":"19","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-10-12T12:00:00Z\u0022\u003EMon, 10\/12\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00719\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E","various_dates":"No"},{"id":"20","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-08T16:00:00Z\u0022\u003EFri, 01\/08\/2021 - 16:00\u003C\/time\u003E\n","description":"\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00512\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E","various_dates":"No"},{"id":"71","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00512\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E","various_dates":"No"},{"id":"21","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-01-04T12:00:00Z\u0022\u003EMon, 01\/04\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/renseignements-cliniques.canada.ca\/ci-rc\/conditions?id=244947\u0022\u003ERenseignements cliniques\u003C\/a\u003E","various_dates":"No"},{"id":"22","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T10:00:00Z\u0022\u003EWed, 12\/23\/2020 - 10:00\u003C\/time\u003E\n","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E","various_dates":"No"},{"id":"23","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=bamlanivimab%20OU%20Bamlanivimab\u0022\u003EAvis\u003C\/a\u003E","various_dates":"Yes"}],"nid":"8","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022fr\u0022\u003ETraitement\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/bamlanivimab-fr.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-pm1-fr.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00719\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-10-12T12:00:00Z\u0022\u003EMon, 10\/12\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00512\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-08T16:00:00Z\u0022\u003EFri, 01\/08\/2021 - 16:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00512\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/renseignements-cliniques.canada.ca\/ci-rc\/conditions?id=244947\u0022\u003ERenseignements cliniques\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-04T12:00:00Z\u0022\u003EMon, 01\/04\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-autorisation.pdf\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T10:00:00Z\u0022\u003EWed, 12\/23\/2020 - 10:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=bamlanivimab%20OU%20Bamlanivimab\u0022\u003EAvis\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"Veklury (remdesivir)","brand_name":"Veklury","company_name":"Gilead Sciences Canada Inc","ingredient":"remdesivir","status":"Autoris\u00e9","date_of_approval":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","language":"Fran\u00e7ais","body_text":"\u003Ch2\u003ERenseignements suppl\u00e9mentaires\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/traitements\/remdesivir.html\u0022\u003ECe que vous devriez savoir\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/traitements\/remdesivir\/autorisation.html\u0022\u003EInformations relatives \u00e0 l\u0027autorisation\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/traitements\/remdesivir\/surveillance.html\u0022\u003ESurveillance continue\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n","resources":[{"id":"5","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/veklury-fr.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E","various_dates":"No"},{"id":"6","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/veklury-pm1-fr.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E","various_dates":"No"},{"id":"8","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detail.html?linkID=RDS00669\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E","various_dates":"No"},{"id":"14","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication). \u003C\/span\u003E\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00491\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E","various_dates":"No"},{"id":"72","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-26T13:00:00Z\u0022\u003ETue, 01\/26\/2021 - 13:00\u003C\/time\u003E\n","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00491\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E","various_dates":"No"},{"id":"10","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222020-10-30T12:00:00Z\u0022\u003EFri, 10\/30\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551\u0022\u003ERenseignements cliniques\u003C\/a\u003E","various_dates":"No"},{"id":"15","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/avis-conformite\/conditions\/avis-admissibilite-veklury-240551.html\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E","various_dates":"No"},{"id":"7","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=remdesivir%20OU%20veklury\u0022\u003EAvis\u003C\/a\u003E","various_dates":"Yes"},{"id":"13","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-11-26T12:00:00Z\u0022\u003EThu, 11\/26\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EUne mise \u00e0 jour de Sant\u00e9 Canada sur la surveillance continue de l\u0027utilisation du remd\u00e9sivir pour la COVID-19.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/mise-a-jour-remdesivir.html\u0022\u003EMise \u00e0 jour sur le remd\u00e9sivir : surveillance continue\u003C\/a\u003E","various_dates":"No"}],"nid":"9","field_product_type":"\u003Ca href=\u0022https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022fr\u0022\u003ETraitement\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/veklury-fr.html\u0022\u003ERenseignements \u00e0 l\u0026#039;intention des consommateurs\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/veklury-pm1-fr.pdf\u0022\u003EMonographie de produit\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-decision-reglementaire-detail.html?linkID=RDS00669\u0022\u003ESommaire de d\u00e9cision r\u00e9glementaire\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00491\u0022\u003ESommaire des motifs de d\u00e9cision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication). \u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/tableau-activites-postautorisation.html?linkID=SBD00491\u0022\u003ETableau des activit\u00e9s postautorisation (TAPA)\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-26T13:00:00Z\u0022\u003ETue, 01\/26\/2021 - 13:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551\u0022\u003ERenseignements cliniques\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-10-30T12:00:00Z\u0022\u003EFri, 10\/30\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/avis-conformite\/conditions\/avis-admissibilite-veklury-240551.html\u0022\u003EConditions de l\u2019autorisation\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=remdesivir%20OU%20veklury\u0022\u003EAvis\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/mise-a-jour-remdesivir.html\u0022\u003EMise \u00e0 jour sur le remd\u00e9sivir : surveillance continue\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EUne mise \u00e0 jour de Sant\u00e9 Canada sur la surveillance continue de l\u0027utilisation du remd\u00e9sivir pour la COVID-19.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-26T12:00:00Z\u0022\u003EThu, 11\/26\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"Pfizer-BioNTech COVID-19 Vaccine (tozinameran)","brand_name":"Pfizer-BioNTech COVID-19 Vaccine","company_name":"BioNTech Manufacturing GmbH","ingredient":"tozinameran","status":"Authorized By Interim Order","date_of_approval":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","language":"English","body_text":"\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Ch2\u003EMore information\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/pfizer-biontech.html\u0022\u003EWhat you should know\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/pfizer-biontech\/authorization.html\u0022\u003EAuthorization information\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/pfizer-biontech\/monitoring.html\u0022\u003EContinued monitoring\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n","resources":[{"id":"27","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pfizer-biontech-covid-19-vaccine-en.html\u0022\u003EConsumer Information\u003C\/a\u003E","various_dates":"No"},{"id":"28","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-vaccine-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E","various_dates":"No"},{"id":"40","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EVial and carton labels for Pfizer-BioNTech COVID-19 Vaccine with English-only labelling.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-label.pdf\u0022\u003EProduct Label\u003C\/a\u003E","various_dates":"No"},{"id":"29","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00730\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E","various_dates":"No"},{"id":"30","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00510\u0022\u003ESummary Basis of Decision\u003C\/a\u003E","various_dates":"No"},{"id":"70","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00510\u0022\u003EPost-Authorization Activity Table (PAAT)\u003C\/a\u003E","various_dates":"No"},{"id":"37","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-letter.pdf\u0022\u003EHealth Product Risk Communications\u003C\/a\u003E","various_dates":"No"},{"id":"67","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/\u0022\u003EAdverse Events Following Immunization\u003C\/a\u003E","various_dates":"Yes"},{"id":"35","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Company\u2019s\u00a0Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003ERisk Management Plan\u003C\/span\u003E","various_dates":"No"},{"id":"31","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EClinical Information\u003C\/span\u003E","various_dates":"No"},{"id":"32","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-vaccine-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E","various_dates":"No"},{"id":"33","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OR%20%22tozinameran%22\u0022\u003EAdvisories\u003C\/a\u003E","various_dates":"Yes"},{"id":"38","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe steps to Pfizer-BioNTech COVID-19 Vaccination. Your guide to proper storage, handling, and administration for the Pfizer-BioNTech COVID-19 Vaccine.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-steps-leaflet-en.pdf\u0022\u003EStorage, handling, and administration\u003C\/a\u003E","various_dates":"No"},{"id":"39","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EShipping and handling guidelines. To ensure appropriate controls are in place, review the enclosed dry ice safety data sheet before accessing the contents from the thermal shipping container and consult with your occupational health department.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-shipping-handling-guidelines-en.pdf\u0022\u003EShipping and handling guidelines\u003C\/a\u003E","various_dates":"No"}],"nid":"16","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pfizer-biontech-covid-19-vaccine-en.html\u0022\u003EConsumer Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-vaccine-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-label.pdf\u0022\u003EProduct Label\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EVial and carton labels for Pfizer-BioNTech COVID-19 Vaccine with English-only labelling.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-11T12:12:02Z\u0022\u003EThu, 02\/11\/2021 - 12:12\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00730\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00510\u0022\u003ESummary Basis of Decision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-09T12:00:00Z\u0022\u003ETue, 02\/09\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00510\u0022\u003EPost-Authorization Activity Table (PAAT)\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-05T12:00:00Z\u0022\u003EFri, 02\/05\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-09T12:12:12Z\u0022\u003ETue, 02\/09\/2021 - 12:12\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-letter.pdf\u0022\u003EHealth Product Risk Communications\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-12T12:00:00Z\u0022\u003ESat, 12\/12\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/\u0022\u003EAdverse Events Following Immunization\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003ERisk Management Plan\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Company\u2019s\u00a0Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EClinical Information\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-vaccine-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-09T12:00:00Z\u0022\u003EWed, 12\/09\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OR%20%22tozinameran%22\u0022\u003EAdvisories\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-steps-leaflet-en.pdf\u0022\u003EStorage, handling, and administration\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe steps to Pfizer-BioNTech COVID-19 Vaccination. Your guide to proper storage, handling, and administration for the Pfizer-BioNTech COVID-19 Vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/pfizer-biontech-covid-19-shipping-handling-guidelines-en.pdf\u0022\u003EShipping and handling guidelines\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EShipping and handling guidelines. To ensure appropriate controls are in place, review the enclosed dry ice safety data sheet before accessing the contents from the thermal shipping container and consult with your occupational health department.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-11T12:00:00Z\u0022\u003EFri, 12\/11\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2)","brand_name":"Moderna COVID-19 Vaccine","company_name":"Moderna Therapeutics Inc","ingredient":"mRNA-1273 SARS-CoV-2","status":"Authorized By Interim Order","date_of_approval":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","language":"English","body_text":"\u003Csection class=\u0022block block-layout-builder block-field-blocknodevaccinebody clearfix\u0022 data-block-plugin-id=\u0022field_block:node:vaccine:body\u0022\u003E\n\u003Cdiv class=\u0022field field--name-body field--type-text-with-summary field--label-hidden field--item\u0022\u003E\n\u003Ch2\u003EMore information\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/moderna.html\u0022\u003EWhat you should know\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/moderna\/authorization.html\u0022\u003EAuthorization information\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines\/moderna\/monitoring.html\u0022\u003EContinued monitoring\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/section\u003E\n","resources":[{"id":"53","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/moderna-covid-19-vaccine.html\u0022\u003EConsumer Information\u003C\/a\u003E","various_dates":"No"},{"id":"54","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-pm1.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E","various_dates":"No"},{"id":"55","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EVial and carton labels for Moderna COVID-19 Vaccine with English-only labelling.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-label.pdf\u0022\u003EProduct Label\u003C\/a\u003E","various_dates":"No"},{"id":"56","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00736\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E","various_dates":"No"},{"id":"57","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-06T12:00:00Z\u0022\u003EWed, 01\/06\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00511\u0022\u003ESummary Basis of Decision\u003C\/a\u003E","various_dates":"No"},{"id":"69","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-06T13:00:00Z\u0022\u003EWed, 01\/06\/2021 - 13:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00511\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E","various_dates":"No"},{"id":"58","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-letter-20201223.pdf\u0022\u003EHealth Product Risk Communications\u003C\/a\u003E","various_dates":"No"},{"id":"66","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EAdverse Events Following Immunization\u003C\/span\u003E","various_dates":"No"},{"id":"59","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Company\u2019s Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003ERisk Management Plan\u003C\/span\u003E","various_dates":"No"},{"id":"60","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n","resource_link":"\u003Cspan\u003EClinical Information\u003C\/span\u003E","various_dates":"No"},{"id":"61","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E","various_dates":"No"},{"id":"62","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Moderna%20COVID-19%20Vaccine%22%20OR%20%22mRNA-1273%20SARS-CoV-2%22\u0022\u003EAdvisories\u003C\/a\u003E","various_dates":"Yes"},{"id":"63","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe steps to Moderna COVID-19 Vaccination. Your guide to proper storage, handling, and administration for the Moderna COVID-19 Vaccine.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-storage-handling.pdf\u0022\u003EStorage, handling, and administration\u003C\/a\u003E","various_dates":"No"}],"nid":"15","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/moderna-covid-19-vaccine.html\u0022\u003EConsumer Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-22T12:00:00Z\u0022\u003EMon, 02\/22\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-pm1.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-label.pdf\u0022\u003EProduct Label\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EVial and carton labels for Moderna COVID-19 Vaccine with English-only labelling.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00736\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00511\u0022\u003ESummary Basis of Decision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-06T12:00:00Z\u0022\u003EWed, 01\/06\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00511\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-06T13:00:00Z\u0022\u003EWed, 01\/06\/2021 - 13:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-letter-20201223.pdf\u0022\u003EHealth Product Risk Communications\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EHealth Product Risk Communications are published to inform healthcare professionals about issues that can include the safety, or effectiveness, of a health product. It is a communication issued by the market authorization holder containing content approved by Health Canada. All Health Product Risk Communications are posted in Health Canada\u2019s recalls and safety alerts database.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EAdverse Events Following Immunization\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003ERisk Management Plan\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Company\u2019s Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cspan\u003EClinical Information\u003C\/span\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\n\u003Cp\u003ETo be published before March 31, 2021.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-03-31T12:00:00Z\u0022\u003EWed, 03\/31\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Moderna%20COVID-19%20Vaccine%22%20OR%20%22mRNA-1273%20SARS-CoV-2%22\u0022\u003EAdvisories\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on shortages, new approvals, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/moderna-covid-19-vaccine-storage-handling.pdf\u0022\u003EStorage, handling, and administration\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe steps to Moderna COVID-19 Vaccination. Your guide to proper storage, handling, and administration for the Moderna COVID-19 Vaccine.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T12:00:00Z\u0022\u003EWed, 12\/23\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"JNJ-78436735\/Ad26.COV2.S","brand_name":"JNJ-78436735\/Ad26.COV2.S","company_name":"Janssen Inc","ingredient":"Ad26.COV2.S","status":"Under review","date_of_approval":null,"language":"English","body_text":null,"resources":[],"nid":"14","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/16\u0022 hreflang=\u0022en\u0022\u003EVaccine\u003C\/a\u003E","field_vaccine_resources":""},{"title":"Veklury (remdesivir)","brand_name":"Veklury","company_name":"Gilead Sciences Canada Inc","ingredient":"remdesivir","status":"Authorized","date_of_approval":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","language":"English","body_text":"\u003Ch2\u003EMore information\u003C\/h2\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/treatments\/remdesivir.html\u0022\u003EWhat you should know\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/treatments\/remdesivir\/authorization.html\u0022\u003EAuthorization information\u003C\/a\u003E\u003C\/li\u003E\n\t\u003Cli\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/treatments\/remdesivir\/monitoring.html\u0022\u003EContinued monitoring\u003C\/a\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n","resources":[{"id":"5","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222021-02-11T12:00:00Z\u0022\u003EThu, 02\/11\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/veklury-en.html\u0022\u003EConsumer Information\u003C\/a\u003E","various_dates":"No"},{"id":"6","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/veklury-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E","various_dates":"No"},{"id":"8","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/regulatory-decision-summary-detail.html?linkID=RDS00669\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E","various_dates":"No"},{"id":"14","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00491\u0022\u003ESummary Basis of Decision\u003C\/a\u003E","various_dates":"No"},{"id":"72","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-26T13:00:00Z\u0022\u003ETue, 01\/26\/2021 - 13:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00491\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E","various_dates":"No"},{"id":"10","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222020-10-30T12:00:00Z\u0022\u003EFri, 10\/30\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551\u0022\u003EClinical Information\u003C\/a\u003E","various_dates":"No"},{"id":"15","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/qualifying-notice-veklury-240551.html\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E","various_dates":"No"},{"id":"7","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Remdesivir%20OR%20Veklury\u0022\u003EAdvisories\u003C\/a\u003E","various_dates":"Yes"},{"id":"13","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-11-26T12:00:00Z\u0022\u003EThu, 11\/26\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EAn update from Health Canada on the continued monitoring of the use of remdesivir for COVID-19.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/remdesivir-update.html\u0022\u003EUpdate on remdesivir: continued monitoring\u003C\/a\u003E","various_dates":"No"}],"nid":"9","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022en\u0022\u003ETreatment\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/veklury-en.html\u0022\u003EConsumer Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-11T12:00:00Z\u0022\u003EThu, 02\/11\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-updated-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EUpdated Date\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-11T12:12:12Z\u0022\u003EThu, 02\/11\/2021 - 12:12\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/veklury-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/regulatory-decision-summary-detail.html?linkID=RDS00669\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00491\u0022\u003ESummary Basis of Decision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-02T12:00:00Z\u0022\u003EWed, 12\/02\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00491\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-26T13:00:00Z\u0022\u003ETue, 01\/26\/2021 - 13:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551\u0022\u003EClinical Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-10-30T12:00:00Z\u0022\u003EFri, 10\/30\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/qualifying-notice-veklury-240551.html\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-07-27T12:00:00Z\u0022\u003EMon, 07\/27\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Remdesivir%20OR%20Veklury\u0022\u003EAdvisories\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/remdesivir-update.html\u0022\u003EUpdate on remdesivir: continued monitoring\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAn update from Health Canada on the continued monitoring of the use of remdesivir for COVID-19.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-26T12:00:00Z\u0022\u003EThu, 11\/26\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"},{"title":"Bamlanivimab (bamlanivimab)","brand_name":"Bamlanivimab","company_name":"Eli Lilly Canada Inc","ingredient":"bamlanivimab","status":"Authorized By Interim Order","date_of_approval":"\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n","language":"English","body_text":null,"resources":[{"id":"17","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the drug. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/bamlanivimab-en.html\u0022\u003EConsumer Information\u003C\/a\u003E","various_dates":"No"},{"id":"18","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E","various_dates":"No"},{"id":"19","bundle":"vaccine_resources","audience":["Consumers"],"date":"\u003Ctime datetime=\u00222020-10-12T12:00:00Z\u0022\u003EMon, 10\/12\/2020 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00719\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E","various_dates":"No"},{"id":"20","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-01-08T16:00:00Z\u0022\u003EFri, 01\/08\/2021 - 16:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00512\u0022\u003ESummary Basis of Decision\u003C\/a\u003E","various_dates":"No"},{"id":"71","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222021-02-05T14:00:00Z\u0022\u003EFri, 02\/05\/2021 - 14:00\u003C\/time\u003E\n","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00512\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E","various_dates":"No"},{"id":"21","bundle":"vaccine_resources","audience":["Researchers"],"date":"\u003Ctime datetime=\u00222021-01-04T12:00:00Z\u0022\u003EMon, 01\/04\/2021 - 12:00\u003C\/time\u003E\n","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=244947\u0022\u003EClinical Information\u003C\/a\u003E","various_dates":"No"},{"id":"22","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"\u003Ctime datetime=\u00222020-12-23T10:00:00Z\u0022\u003EWed, 12\/23\/2020 - 10:00\u003C\/time\u003E\n","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E","various_dates":"No"},{"id":"23","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":"\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Bamlanivimab%20OR%20bamlanivimab\u0022\u003EAdvisories\u003C\/a\u003E","various_dates":"Yes"}],"nid":"8","field_product_type":"\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/17\u0022 hreflang=\u0022en\u0022\u003ETreatment\u003C\/a\u003E","field_vaccine_resources":"  \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/bamlanivimab-en.html\u0022\u003EConsumer Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the drug. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-pm1-en.pdf\u0022\u003EProduct Monograph\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-11-20T12:00:00Z\u0022\u003EFri, 11\/20\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00719\u0022\u003ERegulatory Decision Summary\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-10-12T12:00:00Z\u0022\u003EMon, 10\/12\/2020 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00512\u0022\u003ESummary Basis of Decision\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-08T16:00:00Z\u0022\u003EFri, 01\/08\/2021 - 16:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/post-authorization-activity-table.html?linkID=SBD00512\u0022\u003EPost-Authorization Activity Table (PAAT) \u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-02-05T14:00:00Z\u0022\u003EFri, 02\/05\/2021 - 14:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=244947\u0022\u003EClinical Information\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222021-01-04T12:00:00Z\u0022\u003EMon, 01\/04\/2021 - 12:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/14\u0022 hreflang=\u0022en\u0022\u003EResearchers\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022\/info\/pdf\/bamlanivimab-authorisation.pdf\u0022\u003EAuthorization Terms \u0026amp; Conditions\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-date field--type-datetime field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDate\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ctime datetime=\u00222020-12-23T10:00:00Z\u0022\u003EWed, 12\/23\/2020 - 10:00\u003C\/time\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n,   \u003Cdiv class=\u0022paragraph paragraph--type--vaccine-resources paragraph--view-mode--default\u0022\u003E\n          \n  \u003Cdiv class=\u0022field field--name-field-audience field--type-entity-reference field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EAudience\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--items\u0022\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/12\u0022 hreflang=\u0022en\u0022\u003EConsumers\u003C\/a\u003E\u003C\/div\u003E\n          \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/taxonomy\/term\/13\u0022 hreflang=\u0022en\u0022\u003EHealth Care Professionals\u003C\/a\u003E\u003C\/div\u003E\n              \u003C\/div\u003E\n      \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-resource-link field--type-link field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EResource link\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Ca href=\u0022https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Bamlanivimab%20OR%20bamlanivimab\u0022\u003EAdvisories\u003C\/a\u003E\u003C\/div\u003E\n          \u003C\/div\u003E\n\n  \u003Cdiv class=\u0022field field--name-field-description field--type-text-long field--label-above\u0022\u003E\n    \u003Cdiv class=\u0022field--label\u0022\u003EDescription\u003C\/div\u003E\n              \u003Cdiv class=\u0022field--item\u0022\u003E\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n\u003C\/div\u003E\n          \u003C\/div\u003E\n\n      \u003C\/div\u003E\n"}]